BFM
CLSD

Boothbay Fund Management’s Clearside Biomedical CLSD Stock Holding History

Boothbay Fund Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26,000
Closed -$538K – 758
2019
Q1 		$538K Buy
+26,000
New +$516K 0.05% 365
2018
Q2 		– Sell
-966
Closed -$156K – 760
2018
Q1 		$156K Buy
+966
New +$118K 0.02% 623

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

Boothbay Fund Management's CLSD Position: Q2 2019 in Review

Boothbay Fund Management sold out of Clearside Biomedical (CLSD) in Q2 2019, closing a stake of 26,000 shares — an estimated $538K sold.

Boothbay Fund Management first reported a position in CLSD in Q1 2018 and held it in 2 quarters. The position peaked at $538K in Q1 2019. 50 funds tracked by Wall St. Rank hold CLSD as of Q2 2019.

  • Boothbay Fund Management reported no remaining Clearside Biomedical position as of Q2 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 26,000 Clearside Biomedical shares in Q2 2019, an estimated $538K.
  • Boothbay Fund Management first reported a position in Clearside Biomedical in Q1 2018 and held it in 2 quarters.
  • Boothbay Fund Management's Clearside Biomedical position peaked at $538K in Q1 2019.
  • 50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2019.

Based on Boothbay Fund Management's 13F filing for Q2 2019, filed 14 Aug 2019.